1 month after treatment | SAVR (n = 40) | TAVR (n = 75) | P value |
---|---|---|---|
C-HADS depression (no., % of total) | |||
mean ± SD | 11.4 ± 3.1 | 10.7 ± 3.6 | 0.285 |
≤ 7 | 4 (10%) | 18 (24%) | 0.082 |
8–10 | 14 (35%) | 15 (20%) | |
≥ 11 | 22 (55%) | 42 (56%) | |
C-HADS anxiety (no., % of total) | |||
mean ± SD | 12.2 ± 3.4 | 10.9 ± 3.8 | 0.069 |
≤ 7 | 2 (5%) | 20 (26.7%) | 0.018 |
8–10 | 12 (30%) | 16 (21.3%) | |
≥ 11 | 26 (65%) | 39 (52%) | |
WHOQOL-OLD (mean ± SD) | 34.7 ± 14.0 | 44.1 ± 12.4 | < 0.001 |
CFS (no., % of total) | |||
mean ± SD | 6.6 ± 1.6 | 5.5 ± 1.8 | 0.002 |
1–3 | 0 | 15 (20%) | 0.017 |
4–7 | 29 (72.5%) | 49 (65.3%) | |
8–9 | 11 (27.5%) | 11 (14.7%) | |
4 months after treatment | SAVR (n = 38) | TAVR (n = 70) | P value |
C-HADS depression (no., % of total) | |||
mean ± SD | 12.5 ± 3.7 | 11.9 ± 3.9 | 0.445 |
≤ 7 | 4 (10.5%) | 14 (20%) | 0.216 |
8–10 | 9 (23.7%) | 9 (12.9%) | |
≥ 11 | 25 (65.8%) | 47 (67.1%) | |
C-HADS anxiety (no., % of total) | |||
mean ± SD | 12.5 ± 3.1 | 11.4 ± 4.2 | 0.147 |
≤ 7 | 2 (5.3%) | 16 (22.9%) | 0.04 |
8–10 | 12 (31.6%) | 13 (18.6%) | |
≥ 11 | 24 (63.2%) | 41 (58.6%) | |
WHOQOL-OLD (mean ± SD) | 39.6 ± 13.1 | 41.1 ± 14.0 | 0.586 |
CFS (no., % of total) | |||
mean ± SD | 6.5 ± 1.7 | 5.6 ± 1.7 | 0.006 |
1–3 | 0 | 11 (15.7%) | < 0.001 |
4–7 | 26 (68.4%) | 7 (10%) | |
8–9 | 12 (31.6%) | 52 (74.3%) | |
8 months after treatment | SAVR (n = 28) | TAVR (n = 59) | P value |
C-HADS depression (no., % of total) | |||
mean ± SD | 13.1 ± 3.4 | 9.9 ± 3.8 | < 0.001 |
≤ 7 | 0 | 20 (33.9%) | 0.007 |
8–10 | 8 (28.6%) | 12 (20.3%) | |
≥ 11 | 20 (71.4%) | 27 (45.8%) | |
C-HADS anxiety (no., % of total) | |||
mean ± SD | 12.1 ± 2.8 | 10.3 ± 3.7 | 0.024 |
≤ 7 | 0 | 16 (27.1%) | 0.017 |
8–10 | 9 (32.1%) | 9 (15.3%) | |
≥ 11 | 19 (67.9%) | 44 (74.6%) | |
WHOQOL-OLD (mean ± SD) | 40.0 ± 11.9 | 42.3 ± 12.9 | 0.423 |
CFS (no., % of total) | |||
mean ± SD | 6.8 ± 1.6 | 5.2 ± 1.8 | < 0.001 |
1–3 | 0 | 14 (23.7%) | < 0.001 |
4–7 | 9 (32.1%) | 37 (62.7%) | |
8–9 | 19 (67.9%) | 8 (13.6%) |